Lucentis (ranibizumab) is a prescription drug used to treat certain eye conditions. It comes as a liquid solution for injection into your eye by an ophthalmologist. The typical dosing frequency is ...

The US FDA has approved a new biosimilar of Roche and Novartis' blockbuster ophthalmology therapy Lucentis – Coherus BioSciences' Cimerli – which its developer claims is the first to be fully ...

Lucentis' main patents are not due to expire in Europe until next year, but Samsung Bioepis and Biogen are now poised to roll out the drug as soon the intellectual property on the drug lapses.

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell ...

Mumbai: Global pharma major Lupin Limited has announced that it has received approval from the United States Food and Drug ...

This study will evaluate the safety and efficacy of two dose levels (high and low doses) of the drug compared with Roche’s RHHBY Lucentis (ranibizumab) in patients with DME. Restoret was added ...

Diabetic Macular Edema Market valuation is set to cross USD 4,642.9 million by 2034, at a CAGR of 1.2% through 2034.

Teva Pharmaceutical Industries Limited’s TEVA stock has risen 72.5% so far this year compared with an increase of 17.9% for ...

For wet AMD, there are several anti-VEGF medications like Avastin, Lucentis and Eylea that can stop vision loss and may even ...

Clinuvel says its share price weakness is typical of its peers. Meanwhile Opthea's trial timeline is on track and CMP is back ...